The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients
本文档由 kangminhuo1957 分享于2016-09-05 16:46
The combination of circulating Ang1 and Tie2 levels predict progression free survival advantage in Bevacizumab-treated ovarian cancer patients
分享:
君,已阅读到文档的结尾了呢~~